Obeldesivir for COVID-19
(OAKTREE Trial)

Recruiting in Palo Alto (17 mi)

+168 other locations

Age: < 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Gilead Sciences

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing obeldesivir to see if it is safe and effective for treating COVID-19 in people who are not at high risk of severe illness. Researchers will also study how much of the drug enters the blood and how long it stays in the body.

Eligibility Criteria

This trial is for non-hospitalized individuals with COVID-19 who have symptoms like cough, fatigue, body aches, shortness of breath, headache or sore throat for no more than 3 days. Participants must have tested positive for COVID-19 recently and should not be at high risk of severe disease.

Inclusion Criteria

I experience muscle or body aches.

I have a cough.

I experience shortness of breath.

+7 more

Participant Groups

The study is testing the safety and effectiveness of Obeldesivir in treating COVID-19. It will compare how people respond to Obeldesivir versus a placebo (a substance with no active drug). The study also looks at how the body processes the drug.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: ObeldesivirExperimental Treatment1 Intervention

Participants will receive obeldesivir 350 mg twice daily for 5 days.

Group II: Obeldesivir PlaceboPlacebo Group1 Intervention

Participants will receive obeldesivir placebo twice daily for 5 days.